Therapeutic Success with novel blood washing therapy - Interview with Dr. Ahmed Sheriff

Hennigsdorf, August 2021 - The medical technology company Pentracor GmbH, based in Hennigsdorf near Berlin, publishes an interview with CEO Dr. Ahmed Sheriff.

The innovative and cutting-edge therapy CRP apheresis convinces.

Avoiding serious tissue damage in myocardial infarction and preserving cardiac output. A clinical study on CRP apheresis after myocardial infarction showed significantly positive results. Other cases in clinical practice support these results. Similarly, 9 Covid-19 patients - one before and the others in intensive care - have recovered. The majority were already on artificial ventilation. Unfortunately, about 50 percent of these patients die under normal conditions when treated according to guidelines.

Sat.1 reports on CRP apheresis as salvation for COVID-19 patients

19.05.2021

The Sat.1 morning show has reported on CRP apheresis treatment for COVID-19 patients.

At the Klinikum Havelhöhe, the therapy is now used for many severely ill Corona patients - with promising results. Nevertheless, all funding applications for a large clinical trial were unsuccessfully rejected. The trial is needed to make the therapy available to COVID-19 patients throughout Germany.

ZDF reports on CRP apheresis as salvation for COVID-19 patients

18.05.2021

ZDF has reported on CRP apheresis treatment for COVID-19 patients.

At the Klinikum Havelhöhe, the therapy is now used for many severely ill Corona patients - with promising results. Nevertheless, all funding applications for a large clinical trial were unsuccessfully rejected. The trial is needed to make the therapy available to COVID-19 patients throughout Germany.

Forum Sanitas reports about the dark side of CRP

07.05.2021

In the 2nd issue 2021 of Forum Sanitas an article about the dark side of CRP has been published.

The latest findings on the pathological action of CRP are summarized and the potential clinical applications of CRP apheresis in acute myocardial infarction, COVID-19, and other conditions are described.

Promising treatment success in patients with severe COVID-19 courses

Hennigsdorf, 21.04.2021 – Pentracor GmbH, a medical technology company based in Hennigsdorf near Berlin (convertible bond ISIN: DE000A289XB9, WKN: A289XB), active in the dynamically growing healthcare sector, has achieved further promising treatment successes with its CE-certified and patent-protected medical product PentraSorb® CRP in patients with severe COVID-19 courses. For example, the Havelhöhe Community Hospital in Berlin has been using Pentracor's new therapeutic extracorporeal treatment method for severely ill COVID-19 patients for several weeks and has already achieved a significant improvement in the patients' clinical condition after a short period of time.